Skip to main content
. Author manuscript; available in PMC: 2015 Sep 10.
Published in final edited form as: Dig Dis Sci. 2014 Feb 7;59(4):886–891. doi: 10.1007/s10620-014-3038-1

Fig. 3.

Fig. 3

Survival over time in end stage liver disease (ESLD) patients with cholestasis. There was a trend favoring a survival advantage for the small LV/IBW group in group 2—patients with cholestasis—which was not statistically significant (X2 = 1.74, p = 0.18). This is opposite from the trend we saw for group 1